ArriVent BioPharma Inc(AVBP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.68 | Insider Own | 24.95% | Shs Outstand | 48.3M | Perf Week | -29.19% |
| Market Cap | 0.73B | Forward P/E | - | EPS next Y | 11.44% | Insider Trans | - | Shs Float | 37.0M | Perf Month | -48.6% |
| Enterprise Value | 0.36B | PEG | - | EPS next Q | -1.05 | Inst Own | 78.5% | Short Float | 18.4% | Perf Quarter | -49.83% |
| Income | -0.16B | P/S | - | EPS this Y | 2.21% | Inst Trans | 6.11% | Short Ratio | 5.83 | Perf Half Y | -50.42% |
| Sales | 0.00B | P/B | 1.96 | EPS next 5Y | 12.46% | ROA | -49.3% | Short Interest | 6.81M | Perf YTD | -26.09% |
| Book/sh | 7.59 | P/C | 1.97 | EPS past 3/5Y | -57.73% -29.43% | ROE | -53.1% | 52W High | -58.5% ($35.83) | Perf Year | -19.49% |
| Cash/sh | 7.57 | P/FCF | - | Sales past 3/5Y | - | ROIC | -44.63% | 52W Low | 30.9% ($11.36) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 8.22% | Gross Margin | - | Volatility(W/M) | 9.84% 9.53% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.84 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.16 | EPS Q/Q | -16.83% | Profit Margin | - | RSI (14) | 32.13 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.16 | Sales Q/Q | - | SMA20 | -14.91% ($17.48) | Beta | 1.42 | Target Price | $25.45 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/12 | SMA50 | -39.93% ($24.75) | Rel Volume | 1.02 | Prev Close | $15.95 |
| Employees | 77 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -6.35% - | SMA200 | -44.83% ($26.95) | Avg Volume(3M) | 1.17M | Price | $14.87 |
| IPO | 2024/1/26 | Option/Short | Yes/Yes | Trades | 8878 | Volume | 1,194,892 | Change | -6.77% |
🧬 ArriVent BioPharma (AVBP) is a US clinical-stage biotech company focused on precision oncology, with a primary emphasis on lung cancer. Its lead asset is firmonertinib, an oral targeted oncology drug designed to selectively act on specific epidermal growth factor receptor mutations in non-small cell lung cancer while offering high blood-brain barrier penetration. Through global clinical trials and the expansion of its antibody-drug conjugate pipeline, the company is targeting oncology areas with significant unmet medical needs.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded about as much as usual. That is 102% of its average volume.
AVBP has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +2.2% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 78.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #181 of 597 in the industry
Based on market cap of $733M.
ARDX#178 Ardelyx Inc $755M PER - 
DNA#179 Ginkgo Bioworks Holdings Inc $755M PER - 
OABI#180 OmniAb Inc $743M PER - AVBP#181 ArriVent BioPharma Inc $733M PER - 
WVE#182 Wave Life Sciences Inc $708M PER - 
FAQ
What kind of company is AVBP?
AVBP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AVBP?
The market cap of AVBP is approximately $733M, ranking 2,830 within its sector.
What is the 52-week high and low for AVBP?
AVBP has recorded a 52-week high of $35.83 and a low of $11.36.
